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Objectives: The obligatory hemodilution resulting from crystalloid priming
of the cardiopulmonary bypass circuit represents a major risk factor for
blood transfusion in cardiac operations. We therefore examined whether
retrograde autologous priming of the bypass circuit would result in decreased
hemodilution and red cell transfusion. Methods: Sixty patients having first-time
coronary bypass were prospectively randomized to cardiopulmonary bypass
with or without retrograde autologous priming. Retrograde autologous prim-
ing was performed at the start of bypass by draining crystalloid prime from the
arterial and venous lines into a recirculation bag (mean volume withdrawal:
880 6 150 ml). Perfusion and anesthetic techniques were otherwise identical
for the two groups. The hematocrit value was maintained at a minimum of 16%
and 23% during and after cardiopulmonary bypass, respectively, in all pa-
tients. Patients were well matched for all preoperative variables, including
established transfusion risk factors. Subsequent hemodynamic parameters,
pressor requirements, and fluid requirements were equivalent in the two
groups. Results: The lowest hematocrit value during cardiopulmonary bypass
was 22% 6 3% versus 20% 6 3% in patients subjected to retrograde autologous
priming and in control patients, respectively (p 5 0.002). One (3%) of 30
patients subjected to retrograde autologous priming had intraoperative trans-
fusion, and seven (23%) of 30 control patients required transfusion during the
operation (p 5 0.03). The number of patients receiving any homologous red cell
transfusions in the two groups during the entire hospitalization was eight of 30
(27%; retrograde autologous priming) versus 16 of 30 (53%; control) (p 5
0.03). Conclusions: These data suggest that retrograde autologous priming is a
safe and effective means of significantly decreasing hemodilution and the
number of patients requiring red cell transfusion during cardiac operations.
(J Thorac Cardiovasc Surg 1998;115:426-39)
Homologous blood transfusions remain a persis-tent risk of cardiac operations. Two to four
donor exposures are required in up to 70% of
patients, despite the recent introduction of many
innovative blood conservation techniques.1-4 In fact,
coronary bypass grafting has been associated with
about 10% of all blood transfusions in the United
States.5 Hemodilution, the direct result of the mix-
ing of the patient’s blood volume with the crystalloid
cardiopulmonary bypass (CPB) circuit prime, is a
unique and obligatory feature of cardiac surgery as
currently practiced that imposes a significant risk
for red blood cell transfusions.6, 7 In this regard, the
decrease in hematocrit value associated with he-
modilution may lead to obligatory red cell transfu-
sions resulting from unacceptably lowered hemato-
crit values during or after cardiac operations.
Incremental improvements have been made in de-
creasing the hemodilution associated with CPB,
such as through the use of “low prime” oxygen-
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ators.6, 7 Nevertheless, we hypothesized that a sig-
nificant margin for minimizing hemodilution and
thereby decreasing homologous red cell transfusions
could be achieved with the use of a technique called
retrograde autologous priming (RAP). With this
technique, the crystalloid CPB prime is evacuated
from the pump circuit at the initiation of bypass in
advance of the patient’s blood column.
Our strategy would bring nearly full circle the
technique of blood versus crystalloid priming. The
CPB circuit had historically been primed with up to
8 units of whole blood. Subsequently, the virtues of
moderate and even “extreme” hemodilution in
terms of blood circulation, microcirculatory flow,
and organ function were advanced,8-12 and use of an
asanguineous pump prime ultimately received wide-
spread acceptance. In 1960, Panico and Neptune13
described a technique to eliminate donor blood
prime from the CPB circuit by instead substituting 1
L of physiologic saline solution. After arterial can-
nulation, the patient’s blood was drained retro-
gradely into the CPB circuit. Panico and Neptune13
demonstrated in a series of 25 patients that the use
of a bloodless prime reduced homologous blood
transfusions. Thirty-seven years later, we now report
a modification of their technique in which we use
currently available technologies that decreases the
number of patients requiring homologous red cell
transfusions associated with “excessive” hemodilu-
tion during CPB.
Patients and methods
Study design. Sixty patients having first-time coronary
bypass were prospectively randomized by envelope selec-
tion without replacement to CPB with (n 5 30) or without
(n 5 30) RAP. Exclusion criteria were age less than 18 or
greater than 85 years, left ventricular ejection fraction less
than 30%, emergency procedure, history of stroke, hemat-
ocrit value less than 30%, and weight less than 55 or
greater than 115 kg. Physicians ordering blood transfu-
sions were blinded for randomization. Informed consent
Fig. 1A. Schema of the RAP technique. 1, Arterial line drainage. While systolic arterial blood pressure is
being maintained greater than 100 mm Hg, the recirculation line clamp is slowly released, and blood travels
through the pump arterial line from the aorta though the filter, into the recirculation line, and up into a
1000 ml transfer bag. 2, Venous reservoir and oxygenator drainage. The line between the oxygenator and
arterial line filter is clamped and the recirculation line is unclamped. The arterial pump is slowly advanced
until the venous reservoir volume drops to 200 ml. At this time, the arterial line filter purge is opened and
the arterial pump is again advanced until the fluid exiting the oxygenator outlet became sanguineous. The
arterial pump is stopped and the pump outlet and recirculation lines are clamped. The recirculation line
is then removed from the 1000 ml bag and attached to the recirculation port on the oxygenator reservoir.
3, Venous line drainage. As bypass is commenced, the venous line prime is drained into the recirculation
bag, and this 1⁄4-inch line is clamped once the venous line fluid becomes sanguineous. The recirculation bag
is rehung to allow for crystalloid transfusion as necessary.
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and was obtained from each patient and the study was
approved by the Investigational Review Board of The
New York Hospital–Cornell Medical Center.
Anesthesia and CPB setup. Patients received loraz-
epam and morphine intramuscularly for premedication
before arrival in the operating room. Anesthesia was
induced with intravenous fentanyl, thiopental, and mida-
zolam. Muscle relaxation was achieved with pancuronium.
After intubation, anesthesia was maintained with a com-
bination of fentanyl, midazolam, and isoflurane. Hemody-
namic monitoring and blood sampling were obtained by
means of radial and pulmonary artery catheters. A urinary
catheter with indwelling temperature probe was used for
urine output measurements and core temperature assess-
ment.
The extracorporeal circuit consisted of a hollow-fiber
membrane with integral cardiotomy (Terumo Medical
Corporation, Somerset, N.J.), centrifugal arterial pump
(Bio-Medicus, Medtronic Bio-Medicus, Eden Prairie,
Minn.), 4:1 “coil in bucket” blood cardioplegia set (Gish
Biomedical Incorporated, Irvine, Calif.), arterial line fil-
ter, and a polyvinylchloride tubing set. The total pump
prime was 1400 ml, which consisted of 1100 ml of elec-
trolyte solution (Plasma-Lyte 7.4, Abbott), 10,000 units
U.S. Pharmacopeia porcine mucosa heparin, 100 ml nor-
mal serum albumin, and 200 ml 20% mannitol. A calcu-
lated volume of intraoperative autologous donation blood
was withdrawn at the start of the operation to yield a CPB
hematocrit value of at least 18%, as previously de-
scribed.14 Initial heparin dosing (300 units/kg) was fol-
lowed by a standard cannulation of the ascending aorta
and right atrium with 20F and 36/51F two-stage venous
cannulas, respectively (Sarns/3M, Inc., Ann Arbor,
Mich.).
RAP. For the implementation of RAP, a 1⁄4-inch recir-
culation line was diverted off the arterial outlet line of the
oxygenator. This line was attached to a 1000 ml blood
transfer bag, which was hung on the pump mast 20 cm
higher than the right atrium. In addition, a 1⁄4-inch line
was “y’d” off the venous line just before its connection to
Fig. 1B. Detailed schema of drainage of arterial line.
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the venous inlet of the oxygenator. During the entire RAP
process, a minimum systolic blood pressure of 100 mm Hg
was maintained with oxymetazoline HCl (Neo-Syneph-
rine), as needed. RAP was implemented in three stages,
beginning after the activated clotting time (International
Technidyne Corporation, Edison, N.J.) reached 400 sec-
onds, as follows (Fig. 1):
1. Arterial line drainage. With the systolic arterial blood
pressure maintained greater than 100 mm Hg, the recir-
culation line clamp was slowly released. This allowed for
the patient’s blood to travel through the pump arterial line
from the aorta through the filter, into the recirculation
line, and up into the 1000 ml transfer bag. Up to 400 ml
was recovered from the pump circuit at this time.
2. Venous reservoir and oxygenator drainage. The line
between the oxygenator and arterial line filter was
clamped and the recirculation line was unclamped. The
arterial pump was slowly advanced until the venous res-
ervoir volume decreased to 200 ml. At this time, the
arterial line filter purge was opened and the arterial pump
was again advanced until the fluid exiting the oxygenator
outlet became sanguineous. The arterial pump was
stopped and the pump outlet and recirculation lines were
clamped. An additional 300 ml was removed in this
manner. The recirculation line was then removed from the
1000 ml bag and attached to the recirculation port on the
oxygenator reservoir. After this, the 1000 ml bag was
lowered to allow for additional drainage from the venous
line.
3. Venous line drainage. As CPB was initiated, almost all
of the 400 ml of pump prime from the venous line was
drained into the recirculation bag. Once the venous line
fluid became sanguineous, this 1⁄4-inch line was clamped.
The bag was then rehung to allow for crystalloid transfu-
sion as necessary. The targeted RAP volume to be with-
drawn was 1100 ml.
Performance of CPB. CPB was otherwise conducted as
per standard practice in all patients. Mean arterial pres-
sure was maintained at or greater than 50 mm Hg, and the
venous reservoir was maintained at a level greater than
Fig. 1C. Detailed schema of venous reservoir and oxygenator.
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400 ml. Standard level sensor and air emboli detectors
were used for protection against air embolism. Left ven-
tricular venting was accomplished by means of the aortic
root cannula. Pericardial blood was aspirated and col-
lected in the reservoir. The hematocrit value was main-
tained at a minimum of 16%. Moderate hypothermia
(bladder temperature $28° C) was used. Nonpulsatile
flow rates during CPB ranged from 1.6 L/min per square
meter during hypothermia up to 2.4 L/min per square
meter during normothermia. The protocol mandated that
hematocrit values be maintained at a level of 28% or less
at all times during hypothermia by adding crystalloid
solution, as needed. After aortic crossclamping, cold
blood cardioplegic solution (15 ml/kg) was given at 15- to
20-minute intervals. Blood gases were managed by the
alpha-stat method. Patients were slowly weaned from
CPB when a bladder temperature of 35.5° C was reached.
Heparin was neutralized with equal doses of protamine
sulfate. Total fluid administration was measured. The
pump contents and any additional fluid in the Cell Saver
System (Sarns, Haemonetics Corp., Braintree, Mass.)
were immediately processed and transfused after the
patient’s condition was deemed stable, and the aortic
cannula was removed. The hematocrit value was main-
tained at a minimum of 23% after CPB.
Postoperative care. All patients were admitted to the
intensive care unit and treated as per standard clinical
practice. Platelets (6-unit pack) were transfused for chest
tube drainage greater than 600 ml in the first 3 hours after
the operation, followed by 2 units of fresh frozen plasma
if subsequent drainage was greater than 100 ml/hr. Car-
diac index was maintained greater than 2.0 L/min per
square meter and mean arterial pressure was maintained
at 60 mm Hg or higher by crystalloid infusion or vasoac-
tive agents, as appropriate.
Data analysis. Data were collected as indicated by a
research nurse who was blinded to the randomization. All
patients were followed up until the day of discharge.
Safety data included continuous intraoperative hemody-
namic and electrocardiographic monitoring and analysis
Fig. 1D. Detailed schema of venous line.
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of the postoperative electrocardiogram for myocardial
infarction, blood urea nitrogen and creatinine for renal
dysfunction, and survey for clinical evidence of cerebro-
vascular accidents. Data were collected and analyzed with
the use of spreadsheet and analytical software (Excel,
Microsoft Corporation, Redmond, Wash., and STATIS-
TIX, Tallahassee, Fla.). By way of normalizing for red cell
transfusions, a corrected hematocrit value was generated
by subtracting the number of packed red cell transfusions
times three from the measured hematocrit value obtained
at all time points after these transfusions. Comparisons
between groups of numeric values were made by means of
a two-sample t test. The x2 test was used for comparison
of proportions.
Results
Definition of populations and performance of
RAP. Sixty adult patients scheduled for nonemer-
gency primary coronary artery bypass were enrolled
in this study over a 3-month period and randomized
to CPB with or without RAP. All enrolled patients
were included in the data analysis. The RAP and
non-RAP groups were closely matched for estab-
lished risk factors for transfusion, including age, sex,
preoperative hematocrit value and red cell mass,
aspirin ingestion, and other intraoperative variables
(Table I). Patients were also closely matched for
coexisting disease (Table II). No patients required
any forms of ventricular assist, such as intraaortic
balloon pumping. No complications or deaths oc-
curred in either the RAP or control group.
A significant fraction of the crystalloid prime
volume was replaced by the circulating blood vol-
ume removed from patients in the RAP group
(mean volume withdrawal: 880 6 150 ml, range: 600
to 1100 ml). This mean volume withdrawal, which
was less than the 1100 ml target volume, reflects the
relative ability to complete RAP in these patients.
So that hemodynamic compromise could be
avoided, systolic blood pressure was maintained at a
minimum of 100 mm Hg during the RAP process, as
described in the Patients and methods section. Al-
though oxymetazoline was used in 13 (43%) patients
in the RAP group to facilitate the performance of
RAP, the total oxymetazoline dose during CPB was
not significantly different in the RAP group from
that in the control patients (0.8 6 1.5 mg vs 1.5 6 2.6
mg, respectively, p 5 0.27). The entire RAP process
was generally accomplished in less than 1 minute,
although occasionally it required up to 5 minutes to
complete. The mean arterial pressure and systemic
vascular resistance were not significantly different 5
minutes after initiation of CPB in RAP compared
with control patients (Fig. 2). The CPB flow rate at
this time point was also similar in the RAP and
control groups (4.5 6 0.6 vs 4.7 6 0.5 L/min,
respectively, p 5 0.18).
Hemodynamic and clinical outcome. The venous
reservoir volume at the onset of CPB was signifi-
cantly lower in the RAP group than in the control
group, but it was maintained well above a safety
threshold of 400 ml (Table III). This difference in
reservoir volume was equalized as CPB continued,
despite the fact that total intraoperative infusion of
crystalloid solution (Table III) and hemodynamic
parameters (Fig. 2) were equivalent for the two
groups. The CPB flow rates were also equivalent in
RAP compared with control patients throughout
CPB (data not shown). The mean arterial pressure
was maintained well above minimal safety margins
in both patient groups at all times, as defined in the
clinical protocol (see Patients and methods). Intra-
operative and postoperative vasopressor administra-
Table I. Patient characteristics and surgical data for
control and RAP groups
Control group
(n 5 30)
RAP group
(n 5 30)
Age (yr) 64 6 8 60 6 9
Female 5/30 8/30
Weight (kg) 82 6 11 81 6 10
BSA (m2) 2.0 6 0.2 2.0 6 0.2
Red cell mass (ml) 2040 6 320 2040 6 390
Preoperative hematocrit (%) 40 6 4 41.6 6 4
NYHA class (III or IV) 16/30 18/30
Ejection fraction (%) 47 6 10 46 6 10
Pump time (min) 83 6 22 76 6 28
Aortic clamp time (min) 45 6 15 41 6 16
IV NTG 3/30 4/30
ASA 11/30 12/30
Distal anastomoses 3.0 6 0.5 2.9 6 0.5
There were no significant differences between groups. All values are
mean 6 standard deviation, except proportions. BSA, Body surface area;
NYHA, New York Heart Association; IV NTG, intravenous nitroglycerin
within 24 hours; ASA, aspirin taken within 7 days.
Table II. Patient risk factors for control group and
RAP group
Control group
(n 5 30)
RAP group
(n 5 30)
Diabetes necessitating medication 4 (13%) 9 (30%)
COPD 3 (10%) 2 (7%)
PVD 4 (13%) 2 (7%)
HTN 15 (50%) 17 (57%)
Smoking history 11 (37%) 8 (27%)
There were no significant differences between groups. COPD, Chronic
obstructive pulmonary disease; PVD, peripheral vascular disease; HTN,
hypertension; Smoking history, smoking within 1 year.
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tion was also similar for the RAP and non-RAP
groups (Table IV). By the end of CPB, RAP vol-
umes had to be reinfused in 19 (63%) of the patients
(volume reinfused 720 6 100 ml). Postoperative
weight gain, measured as an indicator of third-space
fluid sequestration, nevertheless demonstrated a
statistically significant trend toward a lesser increase
36 hours after the operation in the RAP group as
Fig. 2. A, Mean arterial pressure at various time points in RAP and non-RAP groups. B, Systemic vascular
resistance at various time points in RAP and non-RAP groups.
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compared with the control group (Table III). There
were no deaths or clinical evidence of myocardial
infarction, stroke, or renal dysfunction in either of
the groups.
Transfusion and blood conservation indices.
One (3%) of 30 patients in the RAP group received
an intraoperative transfusion, compared with seven
(23%) of 30 control patients (p 5 0.03). Throughout
the entire hospital stay, fewer patients in the RAP
group (8 [27%] vs 16 [53%], p 5 0.03) received
packed red blood cells than did control patients.
Among patients who received a transfusion, the
number of homologous units of blood or blood
products administered was similar in the RAP and
the control groups (Table V).
Hematocrit values were equivalent or greater in
the RAP group than in the control group from the
time of initiation of CPB through the early postop-
erative period, despite the decrease in red cell
transfusions in the former group (Fig. 3). The lowest
hematocrit value during CPB was 22% 6 3% versus
20% 6 3% in the RAP and control groups, respec-
tively (p 5 0.002). Patients subjected to RAP, in
fact, demonstrated even greater hematocrit values
when this value was “corrected” for red blood cell
transfusion (Fig. 4). Hematocrit values that ex-
ceeded the protocol limits were not encountered
during CPB.
Postoperative platelet counts, prothrombin
times, and partial thromboplastin times were not
significantly different in RAP compared with con-
trol patients (data not shown), and although con-
trol patients demonstrated a trend toward greater
chest drainage 6 and 24 hours after CPB, the
difference between the groups was not statistically
significant (Table V). Correspondingly, the trans-
fusion of fresh frozen plasma and platelets was
not significantly different between the two groups
(Table V).
Subset analysis. Additional analysis was per-
formed on patients with a body surface area (BSA)
less than 1.9 m2 (lowest 30th percentile of study
population). The decrease in the number of patients
receiving transfusions in the low BSA group was not
significantly greater than that for patients with a
BSA greater than 1.9 m2 (low BSA, 3 [30%] of 10
patients [RAP] vs 6 [67%] of 9 patients [control]
receiving transfusions; high BSA, 5 [25%] of 20
patients [RAP] vs 10 [48%] of 21 patients [control]
receiving transfusions).
Discussion
In the numerous recent trials, a variety of hemo-
static agents have been demonstrated to result in
dramatic reductions of postoperative blood loss and
decreases in the number of transfusions associated
with cardiac operations, but a significant number of
patients in these studies have continued to require
red cell transfusions.4, 15-17 These findings highlight
the critical contribution of factors other than bleed-
Table III. Fluid administration and RAP volumes during surgery
Control group
(n 5 30)
RAP group
(n 5 30) p Value
Total crystalloid given (ml) 2330 6 620 2420 6 780 NS
RAP volume removed (ml) 0 880 6 150 —
Intraoperative autologous donation (ml) 610 6 360 780 6 390 0.1
Postoperative weight gain (% increase from
preop body weight)
2.4 6 4.4 0.5 6 2.5 0.075
Oxygenator reservoir volume
Within 5 min of CPB 970 6 490 480 6 260* 0.001
Within 30 min of CPB 790 6 490 600 6 250 0.06
Within 60 min of CPB 610 6 320 550 6 330 0.6
Total crystalloid given, Crystalloid given by anesthesiologist or by CPB circuit in excess of pump prime before and during CPB; RAP, volume removed during
RAP procedure (no volume was removed from control patients); Postoperative weight gain, measured 36 hours after operation; Oxygenator reservoir volume,
volume in the venous reservoir during CPB; NS, not significant. Values reported are mean 6 standard deviation.
Table IV. Supportive requirements in the operating
room and ICU for control and RAP groups
Control group
(n 5 30)
RAP group
(n 5 30)
Vasopressors
Operating room 20 (67%) 17 (57%)
ICU 6 (20%) 7 (23%)
Inotropic drugs
Operating room 6 (20%) 5 (17%)
ICU 7 (23%) 8 (27%)
IABP 0 (0%) 0 (0%)
There were no significant differences between groups. ICU, Intensive care
unit; Vasopressor, phenylephrine. Inotropic drugs, dobutamine and epi-
nephrine; IABP, Intraaortic balloon pump.
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ing to the transfusion risk associated with cardiac
operations. The hemodilution associated with the
use of an asanguineous (crystalloid) CPB prime
results in decreased intraoperative and postopera-
tive hematocrit values in patients undergoing car-
diac operations.6, 7, 12 The current study demon-
strated that RAP could safely be used to decrease
the crystalloid pump prime and the hemodilution
associated with this prime volume; in this way the
number of patients requiring red blood cell transfu-
sions could be reduced by avoiding the obligatory
transfusions triggered by hematocrit values de-
creased below minimum safety triggers.
RAP and hemodilution. Patients undergoing car-
diac operations who will require transfusions can be
predicted before the operation by a number of
variables, including red cell mass.14, 18-20 This is
consistent with the assumption that patients with a
low red cell mass are more likely to have low
hematocrit values and therefore require transfu-
Fig. 3. Serial hematocrit values at various time points in RAP and non-RAP groups. POD, Postoperative
day.
Table V. Chest tube drainage and homologous transfusions
Control group
(n 5 30)
RAP group
(n 5 30) p Value
Chest tube drainage (ml)
6 hr 350 6 330 325 6 170 NS
24 hr 710 6 470 660 6 300 NS
Transfusions
Patients given PRBCs intraop. 7 (23%) 1 (3%) 0.03
Patients given PRBCs during length of stay 16 (53%) 8 (27%) 0.03
Patients given platelets and/or FFP 6 (20%) 2 (7%) 0.13
PRBCs (units/patient transfused) 2.2 6 1.1 2.0 6 1.3 NS
Platelets (units/patient transfused) 9.0 6 3.4 6.0 6 0 NS
FFP (units/patient transfused) 2.3 6 1.3 2.0 6 0 NS
Values reported mean 6 standard deviation. PRBC, Packed red blood cells; FFP, fresh frozen plasma; NS, not significant.
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sions after CPB as a result of the proportionately
greater hemodilution caused by CPB in these pa-
tients. For example, a 60 kg woman with a 30%
hematocrit value at the start of CPB would be more
likely than a 90 kg man with the same hematocrit
value to require a transfusion on or shortly after
CPB because of a profound degree of relative
hemodilution. Our own experience has similarly
confirmed that patients weighing less than 70 kg
expended 60% of all the homologous blood prod-
ucts transfused, although they comprised only 40%
of the caseload.7
This was a pilot study designed to determine
whether RAP would be of benefit in the general
cardiac surgery population. Patients were not spe-
cifically preselected into high- or low-risk groups on
the basis of BSA, although patients with extremely
low hematocrit values or red cell mass (as deter-
mined by weight) were eliminated because transfu-
sion probably could not be avoided in these patients
even with maximal RAP. With these exceptions, it
can be concluded from this study that RAP success-
fully reduces transfusions in the general coronary
bypass population.
It is not intuitively obvious whether RAP would
be of greater benefit to patients with low BSA
compared with the general population. Successful
implementation of RAP would likely be more diffi-
cult in patients with a low BSA because the red cell
mass withdrawn would represent a proportionately
greater amount of the patient’s total intravascular
volume and therefore would cause more hemody-
namic compromise. On the other hand, the pump
prime volume would equivalently represent a
greater proportion of these patients’ intravascular
blood volumes and therefore would produce more
profound hemodilution and greater likelihood of
hematocrit values low enough to mandate obligatory
transfusions. A limited analysis was performed on
patients in the current study with a BSA of less than
1.9 m2 (lowest 30th percentile). In fact, the transfu-
sion risk in patients with a low BSA was improved to
a somewhat greater extent than that in patients with
a larger BSA, although greater numbers would be
required to achieve statistical significance in this
analysis.
The hematocrit value resulting from the hemodi-
lution associated with CPB can be directly calcu-
Fig. 4. Serial hematocrit values at various time points in RAP and non-RAP groups, “corrected” for
homologous blood transfusions (three percentage points were subtracted from the hematocrit value for
each unit of homologous red blood cells transfused to that time interval). POD, Postoperative day.
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lated as the product of the patient’s hematocrit
value and the patient’s red cell mass (volume) as a
fraction of the crystalloid CPB prime volume plus
the red cell volume (appendix). Red cell mass, the
product of blood volume times hematocrit value,
can be determined with the use of a nomogram
based on the initial hematocrit value, height, weight,
and gender. Thus the patients in whom RAP may
play a critical role in avoiding transfusion may be
predictable before the operation.
RAP as a blood conservation modality. Although
erythropoietin can be used to minimize hemodilu-
tion by enhancing the total red cell mass,21, 23 RAP
is a more expeditious, inexpensive technique, which
minimizes hemodilution by modifying the inverse
aspect of the hemodilution equation: that is, the
CPB prime volume rather than the red cell mass.
Despite this demonstrated efficacy, patients with
exceedingly low red cell masses, such as severely
anemic patients or those, such as elderly patients,
women, or others with small BSAs, will experience
excessive hemodilution, significantly decreased he-
matocrit values, and increased transfusion risk de-
spite maximal RAP. These patients may therefore
be viewed as remaining candidates for preoperative
erythropoietin therapy, despite the potential appli-
cation of RAP. Although hemoconcentration may
also cause increased concentrations of platelets and
clotting factors and thereby reduce postoperative
bleeding, no direct evidence of this was provided by
our results. RAP can thus not be viewed as a
hemostatic modality.
Safety. As described in this article, RAP is safe
and extremely well tolerated. One potential risk of
RAP, paradoxically, is related to the efficiency of
RAP in minimizing hemodilution in patients under-
going CPB. Early investigators had demonstrated
that an inverse linear relationship exists between
temperature and blood viscosity; blood viscosities
can increase 10% to 30% under the hypothermic
conditions associated with CPB.24-26 Therefore
moderate hemodilution during CPB has been con-
sidered desirable in avoiding this increased viscosity
and potential compromise of the microcirculation,
and such a degree of hemodilution has generally
been provided by a total crystalloid prime.9-11 Be-
cause of these considerations, we maintained a
hematocrit value less than 28% (“less than the blood
temperature”) during CPB by using intraoperative
autologous donation before CPB or by adding crys-
talloid prime during CPB, as required. In fact, with
the use of intraoperative autologous donation, “ex-
cessive” hematocrit values were not encountered
during CPB.
A second theoretical risk of RAP is related to the
potential of hemodynamic instability caused by the
large volumes of crystalloid solution withdrawn dur-
ing the RAP process.6 It is somewhat unexpected in
considering the relative hypovolemia induced by
RAP that a significant volume or pressor require-
ment was not subsequently observed in patients
subjected to RAP to “fill up” or “shrink” the
intravascular space, respectively, and thereby avoid
hypotension. In fact, withdrawal of RAP volumes
was well tolerated, with hemodynamic parameters
and pressor requirements that were equivalent to
those in control patients. Although some patients
did require reinfusion of RAP volumes, clinical
experience suggested that correction of preopera-
tive dehydration minimized the incidence of RAP
reinfusion.
Increased vascular tone induced by neuroendo-
crine mechanisms and intravascular fluid shifts from
the extravascular compartment are two of the nor-
mal adaptive responses to intravascular hypovole-
mia and may thus be regarded as potential physio-
logic responses to RAP. Because the mean arterial
pressure and the systemic vascular resistance were
demonstrated to be similar in the RAP and non-
RAP groups in the current study, it would appear
that fluid shifts, as opposed to an endogenous
pressor response, may account for the lack of an
exogenous volume or pressor requirement noted
in patients undergoing RAP. Such fluid shifts
from the extravascular into the intravascular com-
partment, compensating for the volume depletion
occurring during the RAP process, may further-
more explain the relative postoperative fluid
“loss” noted in RAP versus control groups, as
denoted by the difference in weights noted in
these patients 36 hours after the operation. A
relatively greater colloid oncotic pressure, pro-
duced by substitution of the crystalloid prime with
autologous blood, may also be responsible for a
net extravascular fluid loss and relative weight
decrease in the RAP compared with control pa-
tients. Either or both of these effects may result in
decreased lung water accumulation and expedited
ventilator weaning after cardiac operations, as has
been previously suggested.6, 27 Thus RAP may
generate additional clinical benefits apart from
decreased homologous blood transfusions.
Limitations. The study was designed to be a
small-scale pilot study to assess the safety and
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efficacy of RAP in patients undergoing coronary
bypass. Although a more rigorous randomization
procedure would be appropriate for larger studies,
the technique employed in this study provided the
unbiased creation of equivalent study populations in
this trial.
We used a lower limit on-CPB and post-CPB
hematocrit value of 16% and 23%, respectively,
based on previous consensus findings regarding min-
imum safe hematocrit values with hypothermia and
our own review of neurologic sequelae correlated
with hematocrit values during CPB.28-30 On the
basis of these data, we did not think that hematocrit
values lower than those adopted in this study were
acceptable. We therefore do not believe that our
control transfusion rate was “excessively” increased
as a result of inappropriate transfusion triggers or
that our RAP results were consequently significant
only in reference to inappropriately increased con-
trol transfusion rates. Although the transfusion rate
in our non-RAP group would nevertheless appear to
be excessive, it is consistent with the results from a
number of other trials.1-5
One potential modification of the RAP technique
as described in this study might have included slower
RAP withdrawal, which might have improved the
volume of RAP withdrawn and/or pressor require-
ments. However, the RAP technique performed as
described in this study, with withdrawal over 1 to 5
minutes and with incremental administration of
usually one to three boluses of 100 mgm of oxymeta-
zoline, appeared to be both effective and well toler-
ated.
RAP can be viewed as one of a number of
synergistic techniques that can be used to avoid
transfusions during cardiac operations. Either alone
or as component of a multimodality blood conser-
vation protocol, RAP would appear to be a safe and
inexpensive technique of minimizing hemodilution
and red cell transfusions that are associated with
cardiac operations.
We thank Genia Podwojski, Marie Kilcullen, Pat Es-
posito, Barbara Elmer, Youram Sukhram, James McVey,
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Discussion
Dr. Bradley J. Harlan (San Francisco, Calif.). This is a
well-designed prospective randomized study. The surgical
results were very good, there being no deaths in the 60
patients. This interesting technique, which Dr. Rosengart
describes as having been rediscovered, is essentially a
method of priming with autologous blood, as the crystal-
loid volume is deprimed before and right at the beginning
of CPB. Despite this technique, by the time the patients
left the operating room, the amount of crystalloid solution
that each group had received was exactly the same. The
authors conclude from their data that RAP is a safe and
effective means of decreasing red blood cell transfusion in
cardiac operations, and this is certainly the case at New
York Hospital. However, would it be the case for most
patients undergoing coronary artery bypass, in whom
intraoperative autologous blood donation is not used?
The reason I ask is that the control group had an
unusually high incidence of blood transfusion during
hospital stay, 53%, and a remarkably high incidence of
intraoperative transfusion, 23%, despite the fact that the
average preoperative hematocrit value of this group was
40%. I suspect that the use of intraoperative autologous
blood donation may explain this. Dr. Rosengart, during
CPB in the control group, when the hematocrit value
reached your trigger level for transfusion, why didn’t you
reinfuse the autologously donated blood rather than ex-
pose the patient to a homologous transfusion?
Dr. Rosengart. We did reinfuse the patient’s intraoper-
ative autologous donation blood before transfusing ho-
mologous units of blood.
Dr. Harlan. That was not clear from the manuscript. At
Sutter Memorial, we use a standard crystalloid prime and
autotransfusion in the operating room after CPB, and
most patients receive autotransfusion from the chest tube
drainage in the postoperative period. We tried to find a
similar group of patients, but obviously ours are not
exactly the same as your control group. A very small
proportion of these patients received aprotinin. In 470
patients in whom these techniques were used, our inci-
dence of blood transfusion during hospitalization was
38% and the incidence of intraoperative transfusion was
extremely low. In the postoperative period, did you use
the patient’s chest drainage for autotransfusion?
Dr. Rosengart. We do use mediastinal blood autotrans-
fusion as a technique at New York Hospital; we did not in
the completion of this cohort.
Dr. Harlan. You have shown that the technique is
effective, but I am not sure you have shown that it is safe
yet, because your study comprised a relatively small,
highly selected group of good-risk patients. I wonder
whether you have expanded your indications or the use of
the technique since this study and whether, despite this
expansion, the patients seem to tolerate this hypovolemia
well.
Dr. Rosengart. We first started using RAP several years
ago. We now perform RAP on essentially every patient
that we operate on, with the caveat that if the patient is
high risk or we are concerned about hypovolemia or
hypotension, we will not perform RAP.
We probably attempt to perform RAP on 95% of the
patients, and we are probably successful in delivering a
significant amount of RAP volume in the majority of
patients, at least 75% or 80%. About half of the patients
require retransfusion of some of the RAP volume, and on
average about half of the RAP volume is retransfused or
readministered at some time. It is impressive, however,
that the hematocrit values during CPB are higher than
they would be without the technique. I think RAP is
allowing the patients to avoid being in the operating room
with hematocrit values of 15% or 16%, in which case we
would be compelled to transfuse. Whether we really need
to transfuse at a hematocrit value of 15% or 16% is an
unresolved issue.
Dr. Harlan. This study should stimulate us to review
our methods of perfusion.
Dr. Neal W. Salomon (Lutherville, Md.). We have been
doing the same procedure exactly as you described it for
the past year and have had the same results. However, we
have not done a randomized study. At the meeting of The
American Association for Thoracic Surgery in April 1997,
Richard Engelman’s group from Bay State in Massachu-
setts reported similar results with a resurrection of an old
technique. It is extremely simple, and they have had no
problems. Neither of our groups has done a randomized
trial because we use the technique on almost every patient
and there is no need for an institutional review board
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protocol. We found that we have saved blood in the
operating room, and the perfusionists and operating room
personnel are very enthusiastic about the technique. How-
ever, a significant number of patients will require blood
later during their hospital stay. You do get to an irreduc-
ible minimum. The patients who need transfusion the
least are the ones in whom this technique provides the
best results, and the patients with a small body mass who
are already anemic have less red cell mass, and they are
going to need a blood transfusion regardless. They do
require less blood, however, and I think this simple
procedure should generate considerable enthusiasm. I do
not know whether is more effective than 40 or 80 mg of
furosemide (Lasix) or a hemoconcentrator, but it is free.
You also have to make sure that your anesthesiologist
does not try to compensate for a reduced prime by
infusing 2 L of saline solution.
Dr. Rosengart. I would add that RAP is just one of a
number of techniques that can be used in combination to
decrease blood transfusion. If RAP is successfully accom-
plished and the patient subsequently loses 2 L of blood
because of a coagulopathy, the technique has accom-
plished nothing. One thing that we therefore try to
accomplish with our program is to combine different
synergistic and complementary aspects of blood conserva-
tion to help prevent such a scenario. We therefore focus
on coagulopathy and use aprotinin, aminocaproic acid
(Amicar), and so on, which all play important roles.
Dr. Salomon. And you have to make sure that your
anesthesiologist does not compensate by adding 2 L of
saline solution.
Dr. Thomas A. Pfeffer (Los Angeles, Calif.). You men-
tioned that one of your exclusion criteria was the history
of stroke. Is that still considered?
Dr. Rosengart. No, it is not. That was initially an
exclusion criteria because we initiated this protocol so that
we could implement it as cautiously as possible.
Dr. Pfeffer. You also did not accept patients with
asymptomatic carotid stenosis. Was the reason for origi-
nally excluding those patients concern about hypotension
during the period of RCP?
Dr. Rosengart. Yes. Neurologic complications are of
the gravest concern, and because this was a preliminary
trial, we wanted to err on the side of caution. At this point,
we try to perform RAP on essentially every patient.
Dr. Pfeffer. One of your slides indicated that there was
no significant difference in the mean arterial pressure in
the immediate prebypass period. Yet you also described
the use of oxymetazoline. Were the pressures the same
because those patients automatically received phenyleph-
rine while the blood was being withdrawn?
Dr. Rosengart. About half of the patients received 100
mg boluses of phenylephrine as we started the RAP
process. The total amount of pressor requirements was
the same, however, and the hemodynamics were essen-
tially the same. Whatever compensatory mechanism en-
sues that allows compensation for the net blood with-
drawal associated with RAP is unknown. I presume it is
either an extravascular fluid shift or a change in the
venous capacitance that compensates for this net volume
loss.
Dr. Pfeffer. Finally, what time frame is involved in
withdrawing the blood and priming the circuit this way?
Have there been any patients in whom the procedure was
abandoned because of hemodynamic instability?
Dr. Rosengart. The entire RAP process requires from 1
to 5 minutes (maximum). The procedure is quickly done.
Appendix
The following equations were used to determine on-
CPB hematocrit levels with intraoperative autologous
donation (IAD) and retrograde autologous primine
(RAP). The estimated blood volume was determined
from a previously published nomogram* (abbreviations:
CPB 5 cardiopulmonary bypass; HCT 5 hematocrit;
CPV 5 (circuit prime volume – RAP volume); EBV 5
estimated blood volume; HCTinitial 5 HCT before IAD;
HCTpre-CPB 5 HCT after IAD.
HCTon bypass 5 HCTpreCPB(EBV)/(EBV 1 CPV)
IAD volume 5 EBV(HCTinitial 2 HCTpre CPB)/HCTinitial
*Albert SN, editor. Blood volume and extracellular fluid volumes.
Springfield [IL]: Charles C Thomas; 1972. p. 281-2.
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